Minnesota is currently home to 2104 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
NCT05683691
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
Gender:
Male
Ages:
50 years and above
Trial Updated:
05/14/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Prostate Cancer
Register for Updates
Alzheimer's Disease Neuroimaging Initiative 4
NCT05617014
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study has been to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI4 continues the previously funded ADNI1, ADNI-GO, ADNI2, and ADNI3 studies that have combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
05/14/2024
Locations: Mayo Clinic Alzheimer's Disease Research Center, Rochester, Minnesota
Conditions: Mild Cognitive Impairment, Alzheimer Disease, Dementia
Register for Updates
A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis
NCT05587309
Recruiting
The objective of the Healing Phase of the study is to evaluate the safety and efficacy of up to 8 weeks of once daily oral administration of BLI5100 versus a PPI control in healing EE. The objective of the Maintenance Phase of the study is to evaluate the safety and efficacy of 24 weeks of once daily oral administration of BLI5100 (low or high dose) versus a PPI control in the maintenance of healed EE.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
05/14/2024
Locations: Research Site 148, Plymouth, Minnesota
Conditions: Erosive Esophagitis
Register for Updates
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054
Recruiting
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: M Health Fairview Cancer Clinic -Edina, Edina, Minnesota
Conditions: Breast Neoplasms
Register for Updates
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
NCT05357690
Recruiting
The purpose of this study is to test if a nerve block procedure called a stellate ganglion block can help decrease the chance of atrial fibrillation after surgery. Atrial fibrillation is the abnormal, fast beating of the upper chambers of the heart. Stellate ganglion blockade has shown to decrease other types of abnormal heart rhythms as well as decrease the chance of atrial fibrillation.
Gender:
All
Ages:
60 years and above
Trial Updated:
05/14/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Atrial Fibrillation
Register for Updates
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease Mediated Proteinuric Kidney Disease
NCT05312879
Recruiting
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Gender:
All
Ages:
Between 10 years and 65 years
Trial Updated:
05/14/2024
Locations: InterMed Consultants, Edina, Minnesota
Conditions: Proteinuric Kidney Disease
Register for Updates
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083
Recruiting
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Mayo Clinic Hospital - Rochester, Rochester, Minnesota
Conditions: Multiple Myeloma
Register for Updates
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
NCT05076175
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
05/14/2024
Locations: Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota
Conditions: Colitis, Ulcerative
Register for Updates
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
NCT05001880
Recruiting
This phase II trial compares the usual treatment alone to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is in a class of medications called antiangiogenic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Peritoneal Malignant Mesothelioma
Register for Updates
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors
NCT04939597
Recruiting
This phase III trial compares memantine to usual treatment in treating patients with primary central nervous system tumors. Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary central nervous system tumors.
Gender:
All
Ages:
Between 4 years and 17 years
Trial Updated:
05/14/2024
Locations: Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota
Conditions: Central Nervous System Carcinoma
Register for Updates
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
NCT04894591
Recruiting
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: MMCORC - HealthPartners Institute, Saint Louis Park, Minnesota
Conditions: Extensive-stage Small-cell Lung Cancer
Register for Updates
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100
Recruiting
The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Mayo Clinic in Rochester, Minnesota, Rochester, Minnesota
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates